Trial Profile
An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Leflunomide (Primary) ; Orotic acid (Primary)
- Indications Kidney disorders; Polyomavirus infections; Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Chang Zheng-Cinkate Pharmaceutical Corporation
- 03 Dec 2018 Status changed from recruiting to discontinued.
- 25 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 25 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.